Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
281-300 of 998 trials

Major Depressive Disorder: NMRA-335140 Study

We are testing a new oral medication for adults with major depressive disorder to see if it helps improve their symptoms compared to a placebo. The study will measure changes in mood and daily functioning over six weeks.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Chronic Kidney Disease: FINESSE Study on Albuminuria Reduction

We are researching how well finerenone and semaglutide can lower albuminuria in patients with chronic kidney disease. The goal is to find the most effective treatment for each individual and explore remote monitoring options.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyNephrology

Fasudil for Early Alzheimer's Disease

We are studying whether fasudil can help prevent memory loss in people with early Alzheimer's disease. The trial will also assess its safety and effects on brain health.

Alzheimer's DiseaseCognitive ImpairmentEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Colorectal Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab alone and with standard chemotherapy for patients with advanced colorectal cancer. The goal is to see how well it works and to ensure it is safe.

Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Severe Hemophilia A: Continued Access to Efanesoctocog Alfa

We are providing ongoing treatment access for patients with severe hemophilia A who completed a previous trial with efanesoctocog alfa. The study aims to gather more information on its safety and effectiveness in preventing and treating bleeding episodes.

Haemophilia AConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Atopic Dermatitis: Long-Term Study of Amlitelimab

We are evaluating the long-term safety and effectiveness of amlitelimab for individuals with moderate to severe atopic dermatitis who have participated in earlier studies. This research aims to better understand how the treatment works over time.

Atopic Dermatitis>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Mycobacterium abscessus: Optimizing Lung Disease Treatment

We are studying the best treatment options for lung disease caused by Mycobacterium abscessus. Our goal is to see how well these treatments clear the infection and how well patients tolerate them.

Mycobacterium Abscessus Infection1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesPulmonology

Schizophrenia: Intensified Treatment Study

We are investigating whether a six-week intensified medication plan helps individuals with schizophrenia who didn't respond to their first treatment. The study looks at changes in symptoms, functioning, and overall well-being compared to standard care.

Schizophrenia and Related Disorders≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Bipolar Depression: New Treatment Approach

We are investigating whether a six-week intensified medication plan helps people with bipolar depression who didn't respond to their first treatment. We’ll compare this new approach to standard care to see which is more effective.

Bipolar Depression≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Major Depressive Disorder: New Treatment Approach

We are studying whether a six-week intensified medication treatment helps people with major depressive disorder who didn't respond to their first treatment. The goal is to see if this new approach improves symptoms and overall well-being compared to standard care.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Niraparib: Long-Term Safety Study for Cancer Patients

We are evaluating the long-term safety and tolerability of niraparib for patients who have previously completed a study and are deemed to benefit from continued treatment. This study helps us understand how well the medication can be tolerated over time.

Advanced Ovarian, Breast, or Prostate CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer: Lower Dose of CDK 4/6-Inhibitors

We are studying whether a lower initial dose of a cancer medication is effective for older breast cancer patients compared to the standard dose. This trial aims to improve treatment outcomes and quality of life for vulnerable patients.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyGynecology and ObstetricsOncology

Pulmonary Sarcoidosis: OATD-01 Treatment Study

We are studying the effects of OATD-01, an oral medication, on reducing lung inflammation in people with active pulmonary sarcoidosis. The trial will also look at safety, lung function, and quality of life.

Pulmonary Sarcoidosis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Non-Hodgkin Lymphoma: BMS-986458 Treatment Study

We are testing a new drug, BMS-986458, for people with relapsed or refractory non-Hodgkin lymphoma. The study aims to understand its safety and how it works alone and with other treatments.

Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Idiopathic Hypersomnia: Melatonin and Light Therapy Study

We are investigating whether a combination of evening melatonin and morning light therapy can help adults with idiopathic hypersomnia feel less sleepy. This study compares the treatment to a placebo to see if it makes a difference.

Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Rheumatoid Arthritis: New Biosimilar Drug Study

We are comparing a new biosimilar drug to Orencia® for patients with moderate to severe rheumatoid arthritis already taking methotrexate. The study will look at effectiveness, safety, and how the body reacts to the treatment.

Rheumatoid Arthritis1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteRheumatology

Heart Failure: Colchicine and Thiamine Study

We are studying whether colchicine and thiamine can help improve heart health in people with heart failure due to ischemic heart disease. The trial looks at their effects on serious heart-related events and hospital visits.

Heart Failure>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Metastatic Uveal Melanoma: IDE196 and Crizotinib Combination

We are studying a new combination treatment for HLA-A2 negative metastatic uveal melanoma to see if it works better than current options. The trial will also evaluate the safety and quality of life for participants.

Uveal Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

ALK Positive Non-Small Cell Lung Cancer: Chemotherapy Plus Lorlatinib

We are studying a combination of chemotherapy and Lorlatinib for patients with ALK positive NSCLC who have had disease progression outside the brain. The goal is to see if this treatment improves outcomes compared to past therapies.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Metastatic Breast Cancer: [177Lu]Lu-NeoB with Capecitabine

We are studying a new treatment combining [177Lu]Lu-NeoB and capecitabine for adults with specific metastatic breast cancer. The goal is to find the best doses and evaluate how well it works after other treatments have failed.

Metastatic Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology